<DOC>
	<DOC>NCT01801150</DOC>
	<brief_summary>Aim: To assess if six months of treatment with CPAP associated with conventional drug therapy, contribute to improved glycemic control in patients with type 2 diabetes and sleep apnea-hypopnea syndrome SAHS)</brief_summary>
	<brief_title>CPAP in Diabetes Type 2 Patients With Sleep Apnea</brief_title>
	<detailed_description>Main objective: To assess the effect of 6 months of CPAP treatment associated with conventional drug therapy on glycemic control in patients with type 2 diabetes and sleep apnea-hypopnea syndrome (SAHS)</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<criteria>subjects 18 to 75 years old; diagnosis of type 2 diabetes mellitus; treatment with diet; oral antidiabetics or insulin stable in the last month; levels of HbA1c&gt; 7.5% (if not supported clinic two controls to confirm with a difference not exceeding 0.5%); overweight or obese (BMI â‰¥ 25 kg/m2) professional drivers, risk profession or respiratory failure; excessive daytime sleepiness is very high (Epworth scale&gt; 18); morbid obesity (BMI&gt; 40 kg/m2); CPAP treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Apnea- hypopnea Syndrome</keyword>
	<keyword>Glycemic control</keyword>
	<keyword>Prevalence</keyword>
	<keyword>SAHS</keyword>
	<keyword>life quality</keyword>
</DOC>